Canterbury DHB


Toxoplasmosis - Treatment

Toxoplasmosis can complicate prolonged and intensive anti-leukaemic chemotherapy of any type but is most likely to occur post-BMT. It is caused by toxoplasma gondii. Toxoplasmosis in BMT recipients occurs as a result of reactivation of latent cysts in seropositive patients following allogeneic transplantation. It usually occurs in the first six months post-BMT. Patients who develop chronic GvHD remain immunocompromised and are at increased risk for toxoplasmosis. See UpToDate website for general information about toxoplasma.

In This Section

Clinical Features

Clinical Features

Toxoplasmosis is a mild condition in patients with normal immune systems. By contrast, toxoplasmosis in the immunosuppressed patient is often life-threatening. In this situation, pneumonia, encephalitis, myocarditis, or fever without obvious cause may occur. There are no specific findings but the patient may have neurological symptoms or the picture may resemble miliary TB or pneumocystis infection.



Note: It is important to start treatment early.

For more information on Pyrimethamine, sulphadiazine, and clindamycin, contact the Haematology pharmacist.

About this Canterbury DHB document (5024):

Document Owner:

Andrew Butler (see Who's Who)

Last Reviewed:

May 2021

Next Review:

May 2023


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5024